Reading DHC? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track DHC free→Reading DHC? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track DHC free→NASDAQReal EstateReit - Healthcare FacilitiesSnapshot 2026-06-16
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is weak. Earnings quality cannot be assessed since the company was unprofitable over the past year. Management's recent track record has been steady. Risk is moderate, and the sector backdrop is a headwind. Compared with sector peers, DHC trades below typical levels. Peer multiples imply a price about 58% above where it trades (it looks cheap on this basis); the read is cheap, value-trap risk. This pattern suggests potential issues due to weak financials and fragile earnings quality. The read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 2 valuation methods, at three horizons. Current price $8.79. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $8.83 DHC trades at 1× p/s, below its 6× p/s peer median. Our $20 fair value sits above the price; low confidence. Analysts: $9.50–$10. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price implies about 57% below a flat-multiple fair value, below our forecast of about 2%. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Real Estate names rated weak grew net income 56% of the time over the next year (vs 55% for the rest of the cohort, n=1506).
Over the trailing year it converted 0.03x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-0.16 → $-0.15 (+3.1% / 30d). 1 raised, 0 cut, 2 covering analysts.
0 upgrades, 0 downgrades / 30d, 2 maintained. 60% of analysts rate Buy.
1 PT revisions / 30d. Avg target 23.8% above current price.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$191.
How much price usually moves either way.
On a bad day, this stock has moved -$395.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $1,569.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Sector revenue growth trends will show if Diversified Healthcare can do better. A rebound may mean recovery.
Confirms one read:Sector revenue growth is now over 5% year over year.
Confirms the other:Sector revenue growth remains below 5% year over year.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for DHC yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
No upside scenarios in the latest snapshot.
No downside scenarios in the latest snapshot.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
RESULTS OF OPERATIONS AND FINANCIAL CONDITION. On May 4, 2026 , Diversified Healthcare Trust, or the Company, issued a summary press release and a detailed earnings presentation announcing the Company's financial results for the quarter ended March 31, 2026. Copies of the Company's summary press release and detailed earnings presentation are furnished as Exhibits 99.1 and 99.2 hereto, respectively.
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
$9.50 – $10.50 (median $10.00) · 3 analysts · as of 2026-06-03
Looks cheaper than most peers in the same business.
Self-history needs ~20 months of data.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Health Care REITs.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
DHC Diversified Healthcare Trust | Below typical Show detailsSector percentile: 25 of 100 | inexpensive | moderate |
WELL Welltower | Typical Show detailsSector percentile: 58 of 100 | expensive | low |
VTR Ventas | Typical Show detailsSector percentile: 39 of 100 | expensive | moderate |
OHI Omega Healthcare Investors | Typical Show detailsSector percentile: 66 of 100 | expensive | moderate |
DOC Healthpeak Properties | Above typical Show detailsSector percentile: 79 of 100 | fair | moderate |
5 material management or governance events in the past 24 months, led by M&A activity. Historically, Real Estate names rated stable grew net income 56% of the time over the next year (vs 56% for the rest of the cohort, n=3736).
Not investment advice. As of 2026-06-16.
via XLRE
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Management aims to improve the full year 2026 guidance for Adjusted EBITDAre.
Stated in 2 of last 2 quarters. Adjusted EBITDAre guidance improved from $290M - $305M to $300M - $315M. Despite the improved guidance, the financials show a net income decline from -$21.2M in 2025-Q4 to -$43.3M in 2026-Q1, indicating limited progress in achieving profitability.
“Improved Full Year 2026 Guidance...Adjusted EBITDAre $290M - $305M $300M - $315M $10M”
“Full Year 2026 Guidance”
Management is committed to maintaining a dividend per share of $0.01.
Stated in 3 of last 3 quarters. Dividend per share has been consistently maintained at $0.01. Despite this stability, the company reported a net income decline from -$98.7M in 2024-Q3 to -$43.3M in 2026-Q1, indicating financial challenges.
Management has set a guidance for total recurring CapEx between $100M and $115M for 2026.
Stated in 3 of last 3 quarters. Total recurring CapEx guidance for 2026 is set between $100M and $115M, down from $140M to $160M in 2025. This reduction aligns with the company's focus on capital allocation, though financials show a net income decline from -$98.7M in 2024-Q3 to -$43.3M in 2026-Q1, indicating ongoing financial challenges.
Why it matters: The earnings report will show if the company can improve its weak performance. Investors will look for signs of recovery.
Confirms one read:The earnings report shows revenue growth is now over 5% year over year.
Confirms the other:Earnings report shows revenue decline or flat growth year over year.
RESULTS OF OPERATIONS AND FINANCIAL CONDITION. On February 23, 2026, Diversified Healthcare Trust, or the Company, issued a summary press release and a detailed earnings presentation announcing the Company's financial results for the quarter ended December 31, 2025. Copies of the Company's summary press release and detailed earnings presentation are furnished as Exhibits 99.1 and 99.2 hereto, respectively.
Results of Operations and Financial Condition. On January 14, 2026, we announced that we incurred an incentive management fee of $17.9 million for the 2025 calendar year under our Second Amended and Restated Business Management Agreement, dated as of June 5, 2015, with The RMR Group LLC, as amended to date, or the Business Management Agreement. The incentive management fee is payable by us in cash by January 30, 2026, and we will recognize this expense in our financial statements as of and fo…
Other Events. On January 9, 2026, we received a cash dividend of $27.2 million from AlerisLife Inc., or AlerisLife, in connection with AlerisLife’s sale of all its assets and wind-down of its business. We expect to receive an additional cash dividend of approximately $3.0 million to $7.0 million at the completion of the wind-down of AlerisLife’s business. Warning Concerning Forward-Looking Statements This Current Report on Form 8-K contains statements that constitute forward-looking statement…
Termination of a Material Definitive Agreement. On December 31, 2025, we completed the previously disclosed transition of the management of 116 of our senior living communities managed by AlerisLife Inc., or AlerisLife, to seven different third party managers. In connection therewith, we and AlerisLife mutually terminated our management agreements for our senior living communities managed by AlerisLife. A copy of the termination agreement is filed as Exhibit 10.1 hereto and is incorporated by…
“Dividend per share remains at $0.01.”
“Dividend per share remains at $0.01.”
“Dividend per share remains at $0.01.”
“Total Recurring CapEx $100,000 $115,000.”
“Total Recurring CapEx $100,000 $115,000.”
“2025 Guidance (2) LOW HIGH TOTAL CapEx $140M $160M.”